163 results about "Molecular targets" patented technology

The present invention, among other things, provides technologies for detecting and / or quantifying nucleic acids in cells, tissues, organs, or organisms. Pre-designed barcodes are associated with specific molecular targets through sequential hybridization experiments. A pseudo-color based barcoding scheme is described that overcomes the limitations in the previous generation of the technology. The current method can be applied to both in vitro and in situ analysis.

The invention provides a lung adenocarcinoma prognostic marker and a model, constructs a lung adenocarcinoma prognostic model based on mRNA and lncRNA related to programmed cell death (PCD), and synthesizes bioinformatics analysis and experiments to explore the biological effect of the lncRNA model in lung adenocarcinoma. The prognosis model covers all PCD pathways and various molecules, has stable prognosis prediction accuracy, and can provide a potential molecular target for personalized treatment. According to the method disclosed by the invention, the PCD-related mRNA and lncRNA are integrated to construct a lung adenocarcinoma diagnosis model suitable for Chinese population, so that the identification capability of tumor patient classification is enhanced from multiple aspects, the accuracy and reliability of prognosis prediction are improved, powerful support can be provided for promoting personalized treatment strategies of lung adenocarcinoma patients, and the method is suitable for popularization and application.

Disclosed herein are methods, compositions, and kits related to the identification and / or quantification of target molecules. Furthermore, the disclosure relates to compositions, kits, and methods for detecting and quantifying molecular targets, and especially for detecting and quantifying DNA and RNA The apparatuses and methods. may find use in a variety of applications including prenatal testing detection of pathogens and screening of cancer.

The invention discloses an experimental method based on depletion-type nk cells as a lung cancer treatment target, and relates to the technical field of bioinformatics. Comprising the following steps: S1, data processing; s2, identification of cell subset characteristic genes and cell type annotation; s3, re-clustering the NK cells; s4, NK cell function annotation; s5, differential gene expression analysis; s6, analyzing the difference of activation and inhibition of receptor expression by the RGS1 + NK cells through single cells; s7, performing quasi-time sequence analysis; s8, carrying out cell culture and siRNA transfection; s9, detecting the expression condition of an NK92mi cell activated receptor after the RGS1 is knocked down; s10, carrying out a lactic dehydrogenase release experiment; s11, measuring the IFN-gamma content of the cell supernatant; and S12, virtual screening of drugs. Through analysis and experimental verification, the key function of RGS1 in NK cell depletion in lung cancer is disclosed, and a new and potential molecular target is provided for lung cancer treatment.

The present disclosure provides methods for encoding and decoding signals from barcodes in a plurality of molecular targets from images obtained from imaging based spatial genomics (ISG) experiments. This disclosure sets forth methods, in addition to use of the same, and other solutions to problems in the relevant field.

The invention discloses a three-dimensional multi-layer flaky nano-enzyme, a preparation method thereof and an application of the three-dimensional multi-layer flaky nano-enzyme in immunochromatography detection of micromolecular environmental pollutants, and belongs to the technical field of nano-enzymes and immunochromatography detection. The three-dimensional flaky nano enzyme is elaborately designed by continuously constructing Au nano particles (NP) and AuPt bimetallic NP on a flexible graphene oxide (GO) nano sheet. The nano-enzyme has the beneficial effects that in the nano-enzyme, the two-dimensional GO provides a huge surface area and high stability, hundreds of large AuNPs provide enhanced colorimetric ability and a large-area spherical surface, and tens of thousands of AuPt satellites serve as space catalytic sites and generate excellent peroxidase-like activity. The dual-mode ICA provided by the invention can be used for simultaneously detecting three important drugs, namely gentamicin, clenbuterol and ractopamine, in a real complex sample, and the detection performance of the existing colorimetric ICA technology based on simple catalysis is greatly improved, so that the dual-mode ICA shows huge application potential in the aspect of monitoring small molecular targets in real time under different conditions.

The invention relates to the technical field of biology, in particular to a molecular marker for identifying Holstein cattle with high fecundity and application of the molecular marker. According to the invention, an RBX1 gene is analyzed in cattle 150K genotype chip data, and SNP loci related to first and last hybridization interval characters are found; the method comprises the following steps: establishing a 30x re-sequencing database of high and low reproduction populations for the first time, and autonomously identifying the SNP sites of the high-fecundity Holstein cattle; an important molecular target is provided for the creation of a new gene editing breeding material in the later period, the creation of an autonomous breeding chip in China and the breeding of cattle.

The invention relates to the technical field of biomarkers, in particular to a biomarker composition for diabetic foot ulcer and application of the biomarker composition. The invention provides a biomarker combination for diabetic foot ulcer. The biomarker combination comprises a DDIT4 gene and a PKM gene. According to the invention, by integrating transcriptome sequencing data and single cell sequencing data, biomarkers DDIT4 and PKM closely related to diabetic foot ulcer (DFU) are successfully screened out. The expression of the two genes in a disease group is remarkably up-regulated, and the two genes are stably expressed in different data sets, so that a reliable molecular target is provided for early diagnosis of DFU.

Disclosed herein is Differential Subclone Eradication and Resistance Analysis (DSER), a method developed to identify molecular targets for improved therapy by direct comparison of genomic features of eradicated and resistant subclones in pre-and post-treatment samples from a patient with BRCA2-deficient metastatic prostate cancer. FANCI and EYA4 were identified as candidate DNA repair-related targets for converting subclones from resistant to eradicable, and RNAi-mediated depletion of FANCI confirmed it as a potential target. The EYA4 alteration was associated with adjacent L1 transposon insertion during cancer evolution upon treatment. L1 activation was inhibited by the antiretroviral drug azidothymidine. In conclusion DSER provides an informative intermediate step toward effective precision cancer medicine, especially in cases with dramatic but temporary metastatic tumor regression. L1 transposon activation may be a modifiable source of cancer genomic heterogeneity, suggesting the potential of leveraging newly discovered triggers and blockers of L1 activity to overcome therapy resistance.

The invention relates to the technical field of molecular detection, discloses a KASP molecular marker related to a sheep backfat thickness character, a detection primer group and application of the KASP molecular marker and the detection primer group, and aims to provide a KASP molecular marker for detecting a sheep Chr15: g.12672188 site Tgt; the invention discloses a specific primer group for C variation, which consists of the following three primers: a site T allele typing primer FAM with a nucleotide sequence as shown in SEQ ID NO: 1, and a site T allele typing primer FAM with a nucleotide sequence as shown in SEQ ID NO: 2, the nucleotide sequence of the locus C allele typing primer VIC is as shown in SEQ ID NO: 2. The invention discovers and discloses Tgt of Chr15: g.12672188 site in a sheep genome for the first time; the C single nucleotide polymorphism (SNP) is obviously associated with the backfat thickness character. Association analysis of 118 Auodurau lake rams proves that the back fat thickness of CC and TT genotype individuals is obviously higher than that of TC genotype individuals. The discovery reveals that the two homozygous genotypes of the site are unique genetic patterns of dominant genotypes, and a direct and reliable molecular target is provided for genetic improvement of the sheep backfat thickness.

The present disclosure provides methods for encoding and decoding signals from barcodes in a plurality of molecular targets from images obtained from imaging based spatial genomics (ISG) experiments. This disclosure sets forth methods, in addition to use of the same, and other solutions to problems in the relevant field.

Methods of treating a subject for a dissociative disorder and methods of screening agents for the ability to modulate dissociative and associative states in a subject are provided. In particular, agents that alter rhythmic neural activity in the posteromedial cortex can be used to modulate dissociative and associative states in a subject.

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

The present invention generally relates to systems and methods for imaging or determining nucleic acids in cells or other samples. In some cases, the transcriptome of a cell may be determined. Certain embodiments are generally directed to determining nucleic acids and other targets in a sample at relatively high resolutions. For instance, nucleic acid probes may be applied to sample, and binding of the nucleic acid probes to a target may be amplified using primary and secondary amplifier nucleic acids. In some cases, there is a maximum number of amplifier nucleic acids that can be bound to a target, e.g., the binding is saturatable, and cannot grow indefinitely, even in the presence of abundant reagents. This may be advantageous, for example, for controlling the brightness of each binding event, controlling the size of the amplified regions (e.g., during imaging), and / or for limiting the degree of amplification noise (i.e. the final variation in amplified signal from molecule to molecule), etc. In addition, in some embodiments, the primary and / or secondary amplifier nucleic acids may be formed from only 3 of the 4 naturally-occurring nucleotides, which may result in less secondary structure, faster binding rates, etc. These properties can in some cases facilitate the rapid design of multiple orthogonal amplification sequences, allowing the extension of such an approach to many distinct molecular targets.

The invention provides methods for the detection of molecular targets by digital PCR (dPCR) using a set of universal probes and target-specific tailed primers. Each target is amplified by a unique mixture of primers. The tailed amplicons anneal to a universal set of probes to detect the associated targets. Some targets are amplified using more than one tailed primer. Some targets are amplified using the same multiple tailed primers. In these embodiments, the primers are concentrated to produce a different number of amplicons for each tailed primer, resulting in a different probe-amplicon balance for each target. Two colors of fluorescence intensity are read and plotted as a 2D plot. In the plot, different targets contribute well-resolved clusters. Each cluster in the plot essentially lies a long its own radius allowing for radial multiplexing. The use of a universal set of probes in multiple assays provides for greater flexibility and throughput.

The application discloses a set of molecular targets, primer compositions, methods and applications for identifying respiratory pathogens, the respiratory pathogens are novel coronavirus, influenza A virus and respiratory syncytial virus, and nucleotide sequences of the molecular targets are shown as SEQ ID NO:1-3. The application provides molecular targets, primers and probes for detecting three respiratory pathogens, and establishes a triple real-time RT-RAA detection technology, which can realize rapid identification and differentiation of three respiratory infectious disease pathogens with similar clinical symptoms within 30 minutes, reduces the operation threshold of the existing detection technology, realizes the target of rapidly, simply and accurately identifying and differentiating the three viruses, meets the needs of early clinical diagnosis of infection, provides technical support for precise medication, and has wide application value.

The present invention discloses specific molecular targets of Vibrio vulnificus and a detection method thereof. The nucleotide sequences of the specific molecular targets are as shown in SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4. The present invention not only discloses four specific molecular targets for identifying Vibrio vulnificus, but also provides related specific primer sequences and corresponding PCR detection methods. The present invention does not require physiological and biochemical identification, and has the advantages of short detection time, low cost, strong specificity, etc.

The application discloses a method for improving secretion of antibacterial peptide of Bombyx mori and application thereof, and first proposes application of genes as a regulation target or a regulation marker in improving secretion of antibacterial peptide Gloverin of Bombyx mori, and the application can effectively improve expression of antibacterial peptide Gloverin of Bombyx mori and prolong death time of Bombyx mori infected with nucleopolyhedrovirus by injecting RNAi interference fragments of 7 genes into first-day fifth-instar larvae of Bombyx mori after 6 hours, which provides a new thought for improving expression of antibacterial peptide by taking the like as a molecular target, is favorable for in-depth understanding of a mechanism of Bombyx mori against pathogenic agents, provides a reference for research on Bombyx mori against viruses, and provides a valuable reference for in-depth research on the role of 7 in immune response of Bombyx mori.

The invention relates to application of WDR74 and / or ALYREF as molecular targets in esophageal squamous cell carcinoma diagnosis and treatment, and belongs to the technical field of biological medicine. Aiming at the problem that the esophageal squamous cell carcinoma lacks an effective targeted treatment means, the invention discovers that the expression quantity of WDR74 in tumor tissues is obviously higher than that in para-carcinoma tissues, and the high expression of WDR74 prompts poor prognosis of a patient, and reveals that WDR74 protein and ALYREF protein have specific binding, and the mRNA stability of EGFR is enhanced through ALYREF-mediated m5C RNA epigenetic modification, so that STAT3 phosphorylation is activated, and the treatment effect of the esophageal squamous cell carcinoma is enhanced. Further, the STAT3 is combined with the promoter region of the apoptosis-inhibiting gene MCL1, and finally cell apoptosis is inhibited and tumor formation is promoted. The invention provides a new molecular target and a solution for developing a WDR74 and ALYREF targeting medicine for treating esophageal squamous cell carcinoma and related diagnosis and prognosis evaluation products.

The present disclosure provides methods for scalable amplification of an analyte signal in a sample to achieve spatial localization of the analyte in a biological sample. The present disclosure sets forth the methods, as well as the use of these methods and solutions to other issues in the related art.

The invention discloses specific molecular targets for simultaneously detecting important pathogenic species in enterococcus, a kit and a detection method thereof, the specific molecular targets are respectively an enterococcus specific identification target rmC and three enterococcus species specific targets E6A31RS02140, FHO10RS03365 and EH19712165, then specific primer pairs are respectively designed for the four specific molecular targets, and the specific primer pairs are respectively used for detecting the important pathogenic species in the enterococcus. A multiplex PCR detection system is constructed, whether a sample containing multiple pathogenic species genome DNAs contains enterococcus strains or not can be rapidly and accurately detected and identified, whether the enterococcus strains are enterococcus faecium, enterococcus faecalis and enterococcus avialis or not can be determined, the detection cost is reduced, and the detection efficiency is improved.

The invention discloses a screening method and application of idiopathic pulmonary fibrosis related molecular targets, and belongs to the technical field of biological medicines.The screening method comprises the steps that firstly, distribution deviation of mRNA in transcriptome sequencing data in different samples is evaluated through TPM; and analyzing the metabolic data through PCA. Then, Mfuzz analysis is carried out, expression trends of the genes and metabolites are researched, clustering is carried out according to different expression trends, and the genes and metabolites with trend specificity are recognized. In addition, four control groups are subjected to differential expression analysis, and then enrichment analysis is performed. The differentially expressed genes are then intersected with trend-specific genes to determine potential candidate genes and metabolites. Through correlation analysis of the candidate metabolites, correlation coefficients of 18 hub genes and 5 key metabolites are identified to be greater than 0.85. The other two key genes (Cd163 and Per3) are found by crossing the differentially expressed genes with the identified key genes by using a GEO IPF database.

The present invention relates to an sgRNA sequence for targeted knockout of the IGFL3 gene and its application in enhancing the radiosensitivity of glioblastoma, belonging to the field of biotechnology. The sgRNA sequence is IGFL3-sgRNA-1 or IGFL3-sgRNA-3, and a CRISPR / Cas9 vector for targeted knockout of the IGFL3 gene is constructed using this sgRNA. The above vector was transfected into human glioblastoma cell line U251, and it was identified that the IGFL3 gene could be efficiently knocked out in this cell, and 2 U251 cell lines with knocked-out IGFL3 gene were screened. By targeted knockout of the IGFL3 gene, the radiosensitivity of human glioblastoma cell line U251 can be effectively enhanced. The present invention lays a foundation for studying the role of the IGFL3 gene in the radiosensitivity of glioblastoma, and also provides a powerful tool for developing this gene as a potential molecular target for enhancing the radiosensitivity of glioblastoma.

The application discloses specific molecular targets of Vibrio alginolyticus and Vibrio fluvialis and a detection method thereof, wherein the nucleotide sequence of the specific molecular target of the Vibrio alginolyticus is as shown in SEQ ID NO. 1, and the nucleotide sequence of the specific molecular target of the Vibrio fluvialis is as shown in SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4 or SEQ ID NO. 5. The application not only discloses one specific molecular target for identifying the Vibrio alginolyticus and four specific molecular targets for identifying the Vibrio fluvialis, but also provides related specific primer sequences and corresponding PCR detection methods. The application has the advantages of short detection time, low cost, strong specificity and the like without physiological and biochemical identification.

The invention discloses a campylobacter jejuni rapid detection method and a kit based on a specific molecular target rpoZ. The sequence of the molecular target is as shown in SEQ ID NO. 1. The PCR / qPCR detection kit for detecting campylobacter jejuni is established on the basis of the target rpoZ, has extremely high specificity, only has specific amplification signals for nucleic acid of campylobacter jejuni, and has no cross reaction for other common food-borne pathogenic bacteria such as escherichia coli, salmonella and staphylococcus aureus. Meanwhile, the sensitivity is high, and the nucleic acid detection target can detect the campylobacter jejuni genome DNA as low as 132fg / mu L. The method can effectively detect campylobacter jejuni in samples such as food, is high in specificity, good in accuracy and simple to operate, and can be applied to the fields of food safety and the like.

The invention discloses application of DPP3 as a target spot in preparation of a traditional Chinese medicine for treating and / or preventing pyemia hypersomnia, and relates to the technical field of biomedicine.In-vivo experiments find that the expression level of DPP3 in serum of a pyemia patient is remarkably and positively correlated with the severity of the disease, and the DPP3 has a significant positive correlation with the severity of the disease. Therefore, the DPP3 can be used as a biomarker of severity of the severity of the severity of the severity of the severity However, whether the elevated DPP3 itself will produce a biological effect has not been clear. Based on this, the invention explores the effect of DPP3 with increased septicopyemia in septicopyemia hypersomnia, and finds that after septicopyemia, the DPP3 content in plasma is increased, a hypersomnia phenomenon occurs, and after septicopyemia is induced by a DPP3 knockout mouse, sleep in a dark period is reduced, and a waking period is increased. In addition, after the DPP3 is intravenously injected into the tail of the mouse, non-rapid eye movement sleep in the dark period is increased, and the waking time is shortened. The invention provides a new molecular target and intervention means for the treatment of pyemia-related hypersomnia, and has important clinical application value.

The present invention provides a near-infrared fluorescent probe for active targeting of fibroblast growth factor receptors and a preparation method and application thereof, and relates to the technical field of specific molecular targeted diagnostic reagents. The near-infrared fluorescent probe for active targeting of fibroblast growth factor receptors of the present invention can be quickly cleared in normal tissues and stays in the tumor site for a long time, thereby achieving the effect of in vivo diagnosis, having certain clinical application prospects, and being applied to clinical intraoperative navigation.

The invention provides an application of an SLCO2B1-Ta transcript isomer as a hepatocellular carcinoma diagnosis and treatment target spot. The SLCO2B1-Ta transcript comprises a nucleotide sequence as shown in SEQ ID NO: 1. The invention not only provides a novel molecular target for diagnosis and treatment of hepatocellular carcinoma, but also lays an important experimental foundation for developing a targeted therapy scheme based on an RNA interference technology.

The invention provides an MaSBP17 gene and application thereof in regulating and controlling fruit maturity, and belongs to the technical field of gene engineering. The nucleotide sequence of the MaSBP17 gene is shown as SEQ ID NO: 1 in a sequence table. According to the invention, an SBP transcription factor family in a banana genome is comprehensively and systematically analyzed, a member MaSBP17 with significant expression change in a fruit ripening process is found, and the function of the MaSBP17 is verified by using a virus-induced gene silencing technology. The invention provides an important theoretical basis and a potential molecular target for targeted regulation and control of a banana fruit ripening process, delaying of softening and aging and development of a novel postharvest preservation strategy based on key transcription factors, and has remarkable scientific value and application prospect.

The invention relates to a biomarker used as a diabetic neurogenic bladder (DNB) and a screening method and application thereof. Specifically, the invention provides a biomarker for the neurogenic bladder of diabetes, and the biomarker comprises one or more of ICAM2, VEGFA, JAML, PTPRJ, PTPRC, CD40, IL2RB and NCR1. By utilizing the biomarker provided by the invention, non-invasive and efficient identification of DNB can be realized, and a new molecular target is provided for complication prevention and control of diabetic patients.